156 related articles for article (PubMed ID: 12927565)
21. Cutaneous melanoma and the immunotherapy revolution (Review).
Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M
Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963
[TBL] [Abstract][Full Text] [Related]
22. Normalization Cancer Immunotherapy for Melanoma.
Vesely MD; Chen L
J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Mohr P; Kiecker F; Soriano V; Dereure O; Mujika K; Saiag P; Utikal J; Koneru R; Robert C; Cuadros F; Chacón M; Villarroel RU; Najjar YG; Kottschade L; Couselo EM; Koruth R; Guérin A; Burne R; Ionescu-Ittu R; Perrinjaquet M; Zager JS
Melanoma Manag; 2019 Oct; 6(4):MMT33. PubMed ID: 31871622
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Therapy for Melanoma.
Wada-Ohno M; Ito T; Furue M
Curr Treat Options Oncol; 2019 Jun; 20(8):63. PubMed ID: 31236710
[TBL] [Abstract][Full Text] [Related]
25. Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.
Kim Y; Lee D; Lee J; Lee S; Lawler S
PLoS One; 2019; 14(1):e0211041. PubMed ID: 30689655
[TBL] [Abstract][Full Text] [Related]
26. Duration of adjuvant immunotherapy-biologic, clinical and economic considerations.
Stav I; Gyawali B; Goldstein DA
Med Oncol; 2018 Oct; 35(12):160. PubMed ID: 30374666
[TBL] [Abstract][Full Text] [Related]
27. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.
Oliver DE; Sondak VK; Strom T; Zager JS; Naghavi AO; Sarnaik A; Messina JL; Caudell JJ; Trotti AM; Torres-Roca JF; Khushalani NI; Harrison LB
Melanoma Manag; 2018 Jun; 5(1):MMT02. PubMed ID: 30190928
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy.
Ben-Ami E; Schachter J
Melanoma Manag; 2016 Jun; 3(2):137-147. PubMed ID: 30190882
[TBL] [Abstract][Full Text] [Related]
29. Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.
Baird JR; Monjazeb AM; Shah O; McGee H; Murphy WJ; Crittenden MR; Gough MJ
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):362-373. PubMed ID: 28871985
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Therapy for Melanoma.
Agha A; Tarhini AA
Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
[TBL] [Abstract][Full Text] [Related]
31. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bastholt L; Mortier L; Thomas L; Tahir S; Hauschild A; Hassel JC; Hodi FS; Taitt C; de Pril V; de Schaetzen G; Suciu S; Testori A
N Engl J Med; 2016 Nov; 375(19):1845-1855. PubMed ID: 27717298
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
Boudewijns S; Bol KF; Schreibelt G; Westdorp H; Textor JC; van Rossum MM; Scharenborg NM; de Boer AJ; van de Rakt MW; Pots JM; van Oorschot TG; Duiveman-de Boer T; Olde Nordkamp MA; van Meeteren WS; van der Graaf WT; Bonenkamp JJ; de Wilt JH; Aarntzen EH; Punt CJ; Gerritsen WR; Figdor CG; de Vries IJ
Oncoimmunology; 2016 Jul; 5(7):e1191732. PubMed ID: 27622047
[TBL] [Abstract][Full Text] [Related]
33. Malignant Melanoma.
Perera E; Gnaneswaran N; Jennens R; Sinclair R
Healthcare (Basel); 2013 Dec; 2(1):1-19. PubMed ID: 27429256
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
35. Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
Boudewijns S; Westdorp H; Koornstra RH; Aarntzen EH; Schreibelt G; Creemers JH; Punt CJ; Figdor CG; de Vries IJ; Gerritsen WR; Bol KF
J Immunother; 2016; 39(6):241-8. PubMed ID: 27227325
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
Espinosa E; Soriano V; Malvehy J; Berrocal A; Martínez de Prado P; Quindós M; Soria A; Márquez-Rodas I; Palacio I; Cerezuela P; López-Vivanco G; Alonso L; Samaniego E; Ballesteros A; Puértolas T; Díaz-Beveridge R; de la Cruz-Merino L; López Castro R; López López R; Stevinson K; Del Barrio P; Tornamira MV; Guillém V; Martín-Algarra S
Melanoma Res; 2016 Jun; 26(3):278-83. PubMed ID: 26958991
[TBL] [Abstract][Full Text] [Related]
37. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
Bol KF; Aarntzen EH; Hout FE; Schreibelt G; Creemers JH; Lesterhuis WJ; Gerritsen WR; Grunhagen DJ; Verhoef C; Punt CJ; Bonenkamp JJ; de Wilt JH; Figdor CG; de Vries IJ
Oncoimmunology; 2016; 5(1):e1057673. PubMed ID: 26942068
[TBL] [Abstract][Full Text] [Related]
38. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Therapy of Melanoma.
Davar D; Kirkwood JM
Cancer Treat Res; 2016; 167():181-208. PubMed ID: 26601863
[TBL] [Abstract][Full Text] [Related]
40. [Malignant head and neck melanoma: Part 2: Therapy].
Pföhler C; Vogt T; Müller CS
HNO; 2015 Aug; 63(8):593-602; quiz 603-4. PubMed ID: 26219523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
